Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YKE
|
|||
| Former ID |
DCL000112
|
|||
| Drug Name |
FG-4592
|
|||
| Synonyms |
FG-4592; 808118-40-3; Roxadustat; Roxadustat (FG-4592); UNII-X3O30D9YMX; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; FG4592; ASP1517; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; X3O30D9YMX; CHEMBL2338329; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; FG 4592; AK198953; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anaemia [ICD-11: 3A90; ICD-10: D64.8] | Phase 3 | [1] | |
| Kidney disease [ICD-11: GC2Z] | Phase 3 | [2], [3] | ||
| Company |
FibroGen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16N2O5
|
|||
| Canonical SMILES |
CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3
|
|||
| InChI |
1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
|
|||
| InChIKey |
YOZBGTLTNGAVFU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 808118-40-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16342072, 23432837, 42336191, 80157555, 126661309, 135282345, 136345857, 136367942, 136920326, 141407384, 143499856, 144115977, 152159546, 152233149, 162011559, 162205074, 162664465, 163620750, 163642656, 163686070, 164023429, 164141181, 164159890, 164194037, 164226788, 165246861, 172819755, 173737572, 174006837, 174530844, 186014506, 198987636, 201508204, 223387749, 223682104, 223704717, 226835794, 245922227, 251971106, 252110140, 252166664, 252215423, 252451801
|
|||
| ChEBI ID |
CHEBI:132774
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HIF-prolyl hydroxylase 1 (HPH-1) | Target Info | Inhibitor | [4] |
| HIF-prolyl hydroxylase 2 (HPH-2) | Target Info | Inhibitor | [5] | |
| KEGG Pathway | HIF-1 signaling pathway | |||
| Pathways in cancer | ||||
| Renal cell carcinoma | ||||
| Panther Pathway | Hypoxia response via HIF activation | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01750190) A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8454). | |||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023523) | |||
| REF 4 | The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007 Dec;20(10):647-54. | |||
| REF 5 | Crystalline forms of a prolyl hydroxylase inhibitor. US9115085. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.